Category Archives: Biotechnology

Vistagen Therapeutics Inc (VTGN) is the highest overall rated company in the Biotechnology industry with an overall score of 91. VTGN is up 448.94% so far this year after the company closed yesterday at $2.58. The overall score measures the company's performance based-off both short and long term indicators and means that VTGN scores better than 91% of the overall market.

Vistagen Therapeutics Inc is a strong performer in the Biotechnology industry, which has an average overall score of 36. This means that, on average, the stocks in this industry score higher than 36% of the stock market.

To see InvestorsObserver's Sentiment Score for Vistagen Therapeutics Inc click here.

VTGN has been trading neutral recently. The stock is trading up 21.13% this week following yesterday's decline. VTGN has an average analyst ranking of Strong Buy with an average price target of $5.5.

Click Here to get the full Stock Score Report on Vistagen Therapeutics Inc (VTGN) Stock.

Read the original here:
Is Vistagen Therapeutics Inc (VTGN) a Winner in the Biotechnology Industry? - InvestorsObserver

Seven of the last ten Nobel Prizes in Chemistry have been awarded to advances in biochemistry: the study of chemical processes within and relating to living organisms.

Our understanding of genomics, molecular motors and the editing of genes, together with advances in nanotechnology and AI are at an all-time high. Add to this the rapidly falling costs of the same technology and you have a potent combination.

This combination is about to be both transformative and highly disruptive across many parts of our lives. Just like the ascent of organic chemistry at the turn of the 19th century, our increased focused on proteins is now creating the biorevolution.

We felt just how much the biorevolution has advanced during the pandemic; first, through the speed with which we understood how the virus was disrupting our societies, and then through witnessing vaccine development at unprecedented degrees of speed and efficacy.

Our hope of defeating COVID-19 would have been drastically reduced without the existence of major advances in biological sciences.

Across the globe, millions of people have now benefited from research and vaccination campaigns, allowing us to make important steps in overcoming this terrible pandemic. Undoubtedly, we owe this to scientists to a substantial degree. They have used mRNA vaccines also called gene vaccines to help cells form a spike protein similar to the one that exists on the surface of COVID-19 pathogens.

The technology available has led scientists to be able to create safe and effective vaccines that will eventually allow us to resume our normal lives or at least some new rendition of it.

Bluntly put, our hope of defeating COVID-19 would have been drastically reduced without the existence of these advances in biological sciences. The development of COVID-19 vaccines is an example of biological transformation that has greatly impacted the world and our lives, but mRNA vaccines and gene sequencing are only the tip of the iceberg for the biorevolution.

Beyond being COVID-19's rescue parachute

The biorevolution has the potential to help address some of the most urgent global challenges, from climate change to pandemics, chronic diseases and food security for our growing world population.

Biology, life sciences and digitisation are moving ever closer together, enabling new inventions that significantly impact our daily lives. The list goes on as rapid increases in computing power and the emergence of new capabilities in AI, automation and data analytics are further accelerating the pace of innovation and the promise of higher R&D productivity in the life sciences.

Using the biorevolution to build a better world

I do not think it is an overstatement to sat that, with the right intentions and significant levels of investment, the biorevolution could be this generations vehicle towards a better world.

The biorevolution could address around 45% of global diseases using science and technology that already exists.

Biological scientists have been driving revolutionary scientific breakthroughs and advancements for years. McKinsey Global Institute (MGI) estimates that 60% of physical inputs, including food, energy and even the materials for clothes, could be produced through biotechnology. Its estimates also show that biology-based innovations will generate $4 trillion in economic impact over the next few decades.

This is not a concept for some far-away future; similar to the mRNA technology that helped identify and sequence COVID-19, the biorevolution could address around 45% of global diseases using science and technology that already exists. At the convergence of science and technology, advances in biotechnology are already bringing about progress in clinical trials of vaccines, inspiring a search for gene and microbiome therapies and giving scientists invaluable insights into how viruses work.

Bayer aims to play a central role in the biorevolution by harnessing the power of these innovations.

Our investment arm, Leaps by Bayer, collaborates with and invests in companies pioneering gene editing and advancing therapies to cure cancer and genetic diseases. Recently, we announced promising initial results achieved by BlueRock Therapeutics, a Bayer subsidiary that began clinical trials with a new therapeutic approach for Parkinsons disease. The trials will hopefully pave the way for major advances in the battle against this debilitating illness.

Disease treatment and prevention are not only important for human life, but for plant life as well.

In agriculture, biological tools and gene-editing technologies stemming from CRISPR ("clustered regularly interspaced short palindromic repeats" a family of DNA sequences) can make crops more weather- or disease-resistant. This helps farmers to grow more food and to persevere through harsh or changing conditions.

Moreover, biotechnology can help farmers produce a more sustainable food supply and significantly reduce agricultures global environmental footprint. At Bayer, our investments in biotechnology for its application in the agricultural sector are broad and driven by our firm belief in its potential.

They include the use of gene technology to contribute to increased yields and the reduction of the amount of land needed for agriculture thanks to developments in seeds.

Through Leaps, we are working with other companies like Joyn Bio that are using agricultural biotechnology to reduce the environmental impact of synthetic nitrogen. This could be big: ammonium-based fertilisers today are not only the highest input cost for farmers but also a significant contributor to greenhouse gas emissions.

A successful biorevolution requires collaboration

We are convinced that the biorevolution has the potential to advance industries, disrupt supply chains as we know them, and create opportunities for business and innovation. But like with many innovations that hold great potential, challenges do exist.

These challenges are further complicated by the fact that the biorevolution is starting to gain momentum in times in which the world is diverging. Global partnerships in addressing the pressing ethical and regulatory challenges will be key to unleashing the potential of an age focussed not on bytes but on proteins.

This is true for the relationship between the East and the West but also for the way in which the European Union opens up to leverage the possibilities for health and farms alike.

Increasing understanding of the bioevolution

Companies, innovators and scientists alike must be transparent about both advancements in and uses of biotechnology. What's more, in order to promote innovation and to ensure the safety of biotechnology globally, we urgently need regulation that not only allows for, but facilitates, the fast pace of scientific progress.

We are still a long way away from fully realising the potential of the bioevolution. A major game changer would be global collaboration and coordination between regulators, the private sector, governments, associations and institutions, in order to embrace the benefits, but also manage the risks.

Can you imagine a world without hunger, in which humans could live longer lives with fewer diseases, and farmers could produce more food with fewer resources? We are convinced that the bioevolution holds the promise to get us closer to it.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Continued here:
The biorevolution is kicking off. Here's how to harness its opportunities early on - World Economic Forum

The 35 rating InvestorsObserver gives to Evofem Biosciences Inc (EVFM) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 27 percent of stocks in the Biotechnology industry, EVFMs 35 overall rating means the stock scores better than 35 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Evofem Biosciences Inc (EVFM) stock is trading at $2.43 as of 9:45 AM on Monday, Dec 28, an increase of $0.07, or 2.97% from the previous closing price of $2.36. The stock has traded between $2.40 and $2.47 so far today. Volume today is light. So far 155,885 shares have traded compared to average volume of 2,741,457 shares.

Click Here to get the full Stock Score Report on Evofem Biosciences Inc (EVFM) Stock.

Read the original:
Is Evofem Biosciences Inc (EVFM) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Voyager Therapeutics Inc (VYGR) is around the bottom of the Biotechnology industry according to InvestorsObserver. VYGR received an overall rating of 33, which means that it scores higher than 33 percent of all stocks. Voyager Therapeutics Inc also achieved a score of 22 in the Biotechnology industry, putting it above 22 percent of Biotechnology stocks. Biotechnology is ranked 30 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Voyager Therapeutics Inc (VYGR) stock is lower by -4.86% while the S&P 500 is higher by 0.17% as of 11:15 AM on Thursday, Dec 24. VYGR has fallen -$0.41 from the previous closing price of $8.44 on volume of 324,546 shares. Over the past year the S&P 500 has gained 14.09% while VYGR has fallen -43.41%. VYGR earned $1.04 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 7.72.

Click Here to get the full Stock Score Report on Voyager Therapeutics Inc (VYGR) Stock.

View post:
Should You Buy Voyager Therapeutics Inc (VYGR) in Biotechnology Industry? - InvestorsObserver

Cellectar Biosciences Inc (CLRB) is near the top in its industry group according to InvestorsObserver. CLRB gets an overall rating of 80. That means it scores higher than 80 percent of stocks. Cellectar Biosciences Inc gets a 94 rank in the Biotechnology industry. Biotechnology is number 32 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 80 would rank higher than 80 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Cellectar Biosciences Inc (CLRB) stock is down -2.73% while the S&P 500 has risen 0.7% as of 9:45 AM on Monday, Dec 28. CLRB is lower by -$0.06 from the previous closing price of $2.20 on volume of 160,048 shares. Over the past year the S&P 500 has risen 15.76% while CLRB is lower by -5.31%. CLRB lost -$1.19 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Cellectar Biosciences Inc (CLRB) Stock.

Go here to see the original:
Is Cellectar Biosciences Inc (CLRB) the Top Pick in the Biotechnology Industry? - InvestorsObserver

The 66 rating InvestorsObserver gives to Allakos Inc (ALLK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 82 percent of stocks in the Biotechnology industry, ALLKs 66 overall rating means the stock scores better than 66 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Allakos Inc (ALLK) stock has risen 0.58% while the S&P 500 has fallen -0.22% as of 3:25 PM on Tuesday, Dec 22. ALLK is higher by $0.84 from the previous closing price of $144.00 on volume of 295,894 shares. Over the past year the S&P 500 is up 14.35% while ALLK is higher by 41.36%. ALLK lost -$2.74 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Allakos Inc (ALLK) Stock.

Visit link:
Is Allakos Inc (ALLK) a Winner in the Biotechnology Industry? - InvestorsObserver

The 53 rating InvestorsObserver gives to Aquestive Therapeutics Inc (AQST) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 62 percent of stocks in the Biotechnology industry, AQSTs 53 overall rating means the stock scores better than 53 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Aquestive Therapeutics Inc (AQST) stock has fallen -5.9% while the S&P 500 has risen 0.17% as of 11:15 AM on Thursday, Dec 24. AQST has fallen -$0.39 from the previous closing price of $6.68 on volume of 289,118 shares. Over the past year the S&P 500 has risen 14.09% while AQST has risen 3.11%. AQST lost -$1.53 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aquestive Therapeutics Inc (AQST) Stock.

See more here:
Is Aquestive Therapeutics Inc (AQST) The Right Choice in Biotechnology? - InvestorsObserver

The 65 rating InvestorsObserver gives to Stoke Therapeutics Inc (STOK) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 79 percent of stocks in the Biotechnology industry, STOKs 65 overall rating means the stock scores better than 65 percent of all stocks.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Stoke Therapeutics Inc (STOK) stock is down -0.64% while the S&P 500 has risen 0.53% as of 2:32 PM on Wednesday, Dec 23. STOK has fallen -$0.38 from the previous closing price of $59.92 on volume of 143,445 shares. Over the past year the S&P 500 has gained 14.99% while STOK has risen 108.18%. STOK lost -$1.47 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Stoke Therapeutics Inc (STOK) Stock.

Original post:
Is Stoke Therapeutics Inc (STOK) a Winner in the Biotechnology Industry? - InvestorsObserver

A rating of 12 puts AIM ImmunoTech Inc (AIM) near the bottom of the Biotechnology industry according to InvestorsObserver. AIM ImmunoTech Inc's score of 12 means it scores higher than 12% of stocks in the industry. AIM ImmunoTech Inc also received an overall rating of 20, putting it above 20% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 20 would rank higher than 20 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

AIM ImmunoTech Inc (AIM) stock is lower by -2.91% while the S&P 500 has gained 0.39% as of 10:43 AM on Wednesday, Dec 23. AIM is down -$0.06 from the previous closing price of $2.06 on volume of 958,792 shares. Over the past year the S&P 500 has gained 14.83% while AIM has gained 308.16%. AIM lost -$0.44 per share the over the last 12 months.

Click Here to get the full Stock Score Report on AIM ImmunoTech Inc (AIM) Stock.

Read more:
Is AIM ImmunoTech Inc (AIM) a Winner in the Biotechnology Industry? - InvestorsObserver

A rating of 96 puts Anavex Life Sciences Corp (AVXL) near the top of the Biotechnology industry according to InvestorsObserver. Anavex Life Sciences Corp's score of 96 means it scores higher than 96% of stocks in the industry. Anavex Life Sciences Corp also received an overall rating of 86, putting it above 86% of all stocks. Biotechnology is ranked 32 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Anavex Life Sciences Corp (AVXL) stock is down -2.26% while the S&P 500 is up 0.9% as of 10:41 AM on Monday, Dec 28. AVXL is lower by -$0.13 from the previous closing price of $5.75 on volume of 344,926 shares. Over the past year the S&P 500 is higher by 15.99% while AVXL is up 138.14%. AVXL lost -$0.43 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Anavex Life Sciences Corp (AVXL) Stock.

Read the original here:
Where Does Anavex Life Sciences Corp (AVXL) Stock Fall in the Biotechnology Field? - InvestorsObserver